Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Single Arm Trial to Evaluate the Efficacy of Etanercept in Moderate to Severe Rheumatoid Arthritis Patients Who Failed to Respond or Lost a Satisfactory Response to Treatment With Adalimumab When Used as Their First Biologic Agent

NCT01927757 is registered in ClinicalTrials.gov with Amgen as lead sponsor.

NCT NCT01927757
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01927757 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Single Arm Trial to Evaluate the Efficacy of Etanercept in Moderate to Severe Rheumatoid Arthritis Patients Who Failed to Respond or Lost a Satisfactory Response to Treatment With Adalimumab When Used as Their First Biologic Agent
Lead sponsor
Amgen
Phase
Phase 4
Overall status
Terminated
Start date
May 6, 2013
Completion date
June 11, 2015
Enrollment
90 (actual)
Sites
45

Conditions

As the registry lists them; a condition with its own page is linked.

moderate to severe rheumatoid arthritis